Compare HRI & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HRI | SRRK |
|---|---|---|
| Founded | 1965 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Misc Corporate Leasing Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 5.6B |
| IPO Year | 2006 | 2018 |
| Metric | HRI | SRRK |
|---|---|---|
| Price | $109.74 | $49.78 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 12 |
| Target Price | ★ $159.67 | $55.64 |
| AVG Volume (30 Days) | 493.8K | ★ 1.8M |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.69% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $4,376,000,000.00 | N/A |
| Revenue This Year | $10.12 | N/A |
| Revenue Next Year | $6.16 | $534.24 |
| P/E Ratio | $3,465.33 | ★ N/A |
| Revenue Growth | ★ 22.65 | N/A |
| 52 Week Low | $88.45 | $27.07 |
| 52 Week High | $188.35 | $51.63 |
| Indicator | HRI | SRRK |
|---|---|---|
| Relative Strength Index (RSI) | 51.88 | 58.75 |
| Support Level | $88.45 | $42.52 |
| Resistance Level | $130.75 | $51.63 |
| Average True Range (ATR) | 4.78 | 1.89 |
| MACD | 2.70 | 0.16 |
| Stochastic Oscillator | 91.67 | 79.10 |
Herc Holdings is an equipment rental company that was spun out of Hertz Global in 2016. It is currently the third-largest player in North America, after United Rentals and Sunbelt Rentals, with an approximate 6% market share pro forma for its 2025 acquisition of H&E Equipment Services. It serves a similar mix of companies to its peers (industrial, commercial, and residential construction) from its 450 locations targeting the top 100 metropolitan markets in the US. Herc's rental fleet of approximately $7 billion is also similar in composition to its peer group in terms of equipment offered. The company is also pursuing diversification by bundling and increasing specialty solutions for its customer base. Herc's portfolio skews toward local customers versus national accounts (60%/40%).
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.